Search research articles
Contact Us
Filters
Showing results (261-270 of 332) with videos related to
Page
of 34
Sort By:
Journal of Stroke and Cerebrovascular Diseases : the Official Journal of National Stroke Association
|
August 6, 2024
Mortality in acute ischemic stroke patients with new cancer diagnosed during the index hospitalization versus after discharge
Jayan Göcmen, Fabienne Steinauer, Moritz Kielkopf, et al.
International Journal of Stroke : Official Journal of the International Stroke Society
|
May 31, 2024
Prevalence of right-to-left shunt in stroke patients with cancer
Fabienne Steinauer, Philipp Bücke, Eric Buffle, et al.
Haematologica
|
April 6, 2023
Measurable residual disease-guided therapy in intermediate-risk acute myeloid leukemia patients is a valuable strategy in reducing allogeneic transplantation without negatively affecting survival
Jesse M Tettero, Lok Lam Ngai, Costa Bachas, et al.
Bone Marrow Transplantation
|
June 19, 2026
The impact of IPI risk factors on CAR T-cell therapy or allogeneic stem cell transplantation for treatment of relapsed or refractory large B-cell lymphoma (LBCL)
Anna Ossami Saidy, Ariane Boumendil, Peter Dreger, et al.
Haematologica
|
March 26, 2026
Treatment of therapy-related acute myeloid leukemia and acute myeloid leukemia with myelodysplasia-related changes: a comparative analysis of higher-dose intensive 7+3 induction chemotherapy <i>versus</i> liposomal cytarabine and daunorubicin
Dimitrios Kotsos, Patrycja Gradowska, Sjoerd J F Hermans, et al.
Blood Advances
|
August 11, 2020
Prospective long-term follow-up after first-line subcutaneous cladribine in hairy cell leukemia: a SAKK trial
Rudolf Benz, Kornelius Arn, Martin Andres, et al.
American Journal of Hematology
|
March 19, 2026
Flow Cytometry-Based Measurable Residual Disease Assessment in Patients With Acute Myeloid Leukemia Receiving Non-Intensive Chemotherapy
Lukas H Haaksma, Tom Reuvekamp, Kasper J Croese, et al.
Blood
|
January 28, 2010
Gemtuzumab ozogamicin as postremission treatment in AML at 60 years of age or more: results of a multicenter phase 3 study
Bob Löwenberg, Joachim Beck, Carlos Graux, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 5, 2018
Intensified Therapy of Acute Lymphoblastic Leukemia in Adults: Report of the Randomized GRAALL-2005 Clinical Trial
Françoise Huguet, Sylvie Chevret, Thibaut Leguay, et al.
Hematological Oncology
|
December 7, 2023
Hematopoietic cell transplantation and cellular therapies in Switzerland. Evolution over 25 years. A report from the stem cell transplantation and cellular therapies working groups of the SBST 1997-2021
Jakob R Passweg, Helen Baldomero, Marc Ansari, et al.
Page
of 34
Search research articles
Search
Showing results (261-270 of 332) with videos related to
Sort By:
Page
of 34
Journal of Stroke and Cerebrovascular Diseases : the Official Journal of National Stroke Association
|
August 6, 2024
Mortality in acute ischemic stroke patients with new cancer diagnosed during the index hospitalization versus after discharge
Jayan Göcmen, Fabienne Steinauer, Moritz Kielkopf, et al.
International Journal of Stroke : Official Journal of the International Stroke Society
|
May 31, 2024
Prevalence of right-to-left shunt in stroke patients with cancer
Fabienne Steinauer, Philipp Bücke, Eric Buffle, et al.
Haematologica
|
April 6, 2023
Measurable residual disease-guided therapy in intermediate-risk acute myeloid leukemia patients is a valuable strategy in reducing allogeneic transplantation without negatively affecting survival
Jesse M Tettero, Lok Lam Ngai, Costa Bachas, et al.
Bone Marrow Transplantation
|
June 19, 2026
The impact of IPI risk factors on CAR T-cell therapy or allogeneic stem cell transplantation for treatment of relapsed or refractory large B-cell lymphoma (LBCL)
Anna Ossami Saidy, Ariane Boumendil, Peter Dreger, et al.
Haematologica
|
March 26, 2026
Treatment of therapy-related acute myeloid leukemia and acute myeloid leukemia with myelodysplasia-related changes: a comparative analysis of higher-dose intensive 7+3 induction chemotherapy <i>versus</i> liposomal cytarabine and daunorubicin
Dimitrios Kotsos, Patrycja Gradowska, Sjoerd J F Hermans, et al.
Blood Advances
|
August 11, 2020
Prospective long-term follow-up after first-line subcutaneous cladribine in hairy cell leukemia: a SAKK trial
Rudolf Benz, Kornelius Arn, Martin Andres, et al.
American Journal of Hematology
|
March 19, 2026
Flow Cytometry-Based Measurable Residual Disease Assessment in Patients With Acute Myeloid Leukemia Receiving Non-Intensive Chemotherapy
Lukas H Haaksma, Tom Reuvekamp, Kasper J Croese, et al.
Blood
|
January 28, 2010
Gemtuzumab ozogamicin as postremission treatment in AML at 60 years of age or more: results of a multicenter phase 3 study
Bob Löwenberg, Joachim Beck, Carlos Graux, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 5, 2018
Intensified Therapy of Acute Lymphoblastic Leukemia in Adults: Report of the Randomized GRAALL-2005 Clinical Trial
Françoise Huguet, Sylvie Chevret, Thibaut Leguay, et al.
Hematological Oncology
|
December 7, 2023
Hematopoietic cell transplantation and cellular therapies in Switzerland. Evolution over 25 years. A report from the stem cell transplantation and cellular therapies working groups of the SBST 1997-2021
Jakob R Passweg, Helen Baldomero, Marc Ansari, et al.
Page
of 34